Needham & Company Reiterates a 'Buy' on Vivus (VVUS); 3Q11 Review: Awaiting FORTRESS Results in December
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Vivus (NASDAQ: VVUS) price target of $15.00.
Needham analyst says, "Vivus management highlighted upcoming events in a 3Q11 conference call yesterday. Results from FORTRESS, a retrospective analysis of claims databases to assess topiramate risk for birth defects, are expected to be announced in December 2011. The FDA has also reportedly informed the company that another AdCom will be held in 1Q12 to review the Qnexa NDA resubmission."
"We believe risks associated with topiramate/phentermine are manageable, particularly with respect to the new proposed limited label, and are favorably inclined toward Qnexa approval around the PDUFA date in April 2012."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $9.92 yesterday.
Needham analyst says, "Vivus management highlighted upcoming events in a 3Q11 conference call yesterday. Results from FORTRESS, a retrospective analysis of claims databases to assess topiramate risk for birth defects, are expected to be announced in December 2011. The FDA has also reportedly informed the company that another AdCom will be held in 1Q12 to review the Qnexa NDA resubmission."
"We believe risks associated with topiramate/phentermine are manageable, particularly with respect to the new proposed limited label, and are favorably inclined toward Qnexa approval around the PDUFA date in April 2012."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $9.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- TSS Inc (TSSI) PT Lowered to $13 at Needham
- Needham Reiterates Hold Rating on CoreWeave (CRWV)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
